Vor Biopharma Inc. (VOR) Stock Price & Analysis
Vor Biopharma Inc. (VOR) rose 1.48% to USD 19.26 as of July 25, 2026 at 06:10 UTC, according to Nexqual real-time market data.
VOR last closed at USD 18.98; the session ranged USD 18.36–19.63 on volume of 616,581 shares. Market capitalization is $1.04B, with a 52-week range of USD 6.5–53 (NMS). Source: Nexqual, July 25, 2026 at 06:10 UTC.
Key Statistics (as of July 25, 2026 at 06:10 UTC)
| Price | USD 19.26 |
|---|---|
| Change | ▲ 1.48% (up) |
| Previous Close | USD 18.98 |
| Open | USD 18.99 |
| Day Range | USD 18.36 – 19.63 |
| 52-Week Range | USD 6.5 – 53 |
| Volume | 616,581 shares |
| Market Cap | $1.04B |
| Exchange | NMS |
Technical Analysis (VOR)
Nexqual's technical model rates VOR "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:10 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.52 (neutral) |
| vs SMA50 | Above (USD 16.18) |
| MACD | 0.81 (positive) |
Analyst Ratings (VOR)
Wall Street analysts rate VOR "Strong Buy" based on 8 analysts, with a mean price target of USD 37.88 (range USD 18–50), per Nexqual as of July 25, 2026 at 06:10 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 37.88 |
| High Target | USD 50 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (VOR)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.7 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.73 vs est -0.78 ▲ beat |
| 2025-12-31 | USD 307.53 vs est -1.19 ▲ beat |
| 2025-09-30 | USD -121.63 vs est -4.1 ▼ miss |
| 2025-06-30 | USD -251.2 vs est -11.8 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financials & Fundamentals (VOR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 31.15 |
| Total Cash | $491.52M |
| Total Debt | $2.94M |
| Free Cash Flow | $-188.83M |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financial Health Score (VOR)
Nexqual rates Vor Biopharma Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $492M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$150M |
| Efficiency | Mixed — No data |
Ownership (VOR)
| Insider Ownership | +4.27% |
|---|---|
| Institutional Ownership | +74.07% |
| Shares Outstanding | 54.19M |
| Float | 35.67M |
| Short % of Float | +16.09% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Leadership (VOR)
Vor Biopharma Inc. is led by Jean-Paul Kress (age 60), Chairman, President & CEO, per Nexqual as of July 25, 2026 at 06:10 UTC.
| Chairman, President & CEO | Jean-Paul Kress (age 60) |
|---|---|
| Chief Business Officer & CFO | Sandesh Mahatme L.L.M. (age 60) |
| Scientific Founder & Chairman of Scientific Advisory Board | Siddhartha Mukherjee DPHIL (age 54) |
Major Backers & Investors (VOR)
Notable institutional backers of Vor Biopharma Inc. include TCG Crossover Management, LLC, RA Capital Management, L.P., FCPM III Services B.V., according to Nexqual as of July 25, 2026 at 06:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 10.47% |
| RA Capital Management, L.P. | 9.97% |
| FCPM III Services B.V. | 7.6% |
| Venrock Adviser, LLC | 5.61% |
| Frazier Life Sciences Management, L.P. | 4.69% |
| Caligan Partners, LP | 3.55% |
| Great Point Partners LLC | 3.23% |
| Paradigm Biocapital Advisors LP | 3.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.24% |
| State Street | 3.23% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
From Vor Biopharma Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
- The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
- It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMCR | Immunocore Holdings plc | USD 35 | ▼ 1.52% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| BCAB | BioAtla, Inc. | USD 3.37 | ▼ 0.59% |
| SANA | Sana Biotechnology, Inc. | USD 3.18 | ▲ 1.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:10 UTC. This page is informational and not investment advice.